RecruitingNot applicableNCT06504589
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nicole Hamblett
- Principal Investigator
- Deepika Polineni, MD, MPHWashington University School of Medicine
- Enrollment
- 400 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2029
Study locations (20)
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California San Diego, La Jolla, California, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- University of California, San Francisco - Adult Center, San Francisco, California, United States
- University of California, San Francisco - Peds Center, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami, Miami, Florida, United States
- Central Florida Pulmonary Group, Orlando, Florida, United States
- Tampa General Hospital, Tampa, Florida, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06504589 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS